The novel MEK1/2 inhibitor produced an ORR of 36% and a median OS of 17.3 months in all-comers, supporting its advancement in the phase 3 MAPKeeper 301 trial.
Advancing MEK-Directed Strategies in Metastatic Pancreatic Cancer
Advertisement
Advertisement